As many veteran investors can attest, biotech stocks are tricky to trade. Their potential upside is enormous, but so is their risk. Too many of these names end up being complete busts. If you pick the ...

Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing ...

Recursion Pharmaceuticals (NASDAQ: RXRX) has been a pioneer in using artificial intelligence (AI) to improve the drug discovery process. The company, founded in 2013, has been working on that project ...

Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though. Recursion may not be a meme stock, but that doesn't make it a ...

Biotech Recursion announced a definitive merger agreement with drug design and development company Exscientia on Thursday morning. The combined company, which is expected to yield annual synergies of ...

The advent of AI is changing how drugs are developed by predicting likely outcomes without extensive testing. While drug companies seem hesitant to test-drive this tech, they'll likely eventually warm ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...